<DOC>
	<DOCNO>NCT00851370</DOCNO>
	<brief_summary>The objective conduct exploratory study effect Omalizumab COPD patient elevate IgE . Exploratory outcomes include determine whether Omalizumab use : reduces exacerbation COPD patient ; improve rescue medication use , decrease ICS use , modify Medical Research Council ( MMRC ) dyspnea score , St. George 's Respiratory Questionnaire ( SGRQ ) , 6-minute walk distance ( 6MWD ) , forced expiratory volume one second ( FEV1 ) ( latter 3 BMI make BODE score ) , residual volume ( RV ) , total lung capacity ( TLC ) , exhale nitric oxide ( ENO ) , determination C-reactive protein ( CRP ) .</brief_summary>
	<brief_title>Exploratory Study Xolair Chronic Obstructive Pulmonary Disease Patients With Elevated IgE Levels</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Smokingrelated COPD age 40 70 yr . Total IgE 30700 IU positive RAST skin prick test result one perennial environmental allergen ( e.g . dust mite ( Dermatophagoides farinae , Dermatophagoides pteronyssinus ) , cockroach , dog , cat . ) Any race sex ; woman childbearing potential require use acceptable method birth control negative pregnancy test History ≥2 exacerbations 2 yr previous enrollment date An exacerbation define increase new onset one following : cough , sputum , wheeze , dyspnea , chest tightness duration least 3 day require antibiotic systemic steroid treatment . The severity exacerbation determine follow : Mild : Home management , without contact health care provider , unscheduled office visit Moderate : Requiring visit emergency department Severe : Requiring hospitalization Very Severe : Requiring intubation medical ventilation Postbronchodilator FEV1 3064 % predict ; first 5 subject enrol required postbronchodilator FEV1 5064 % Postbronchodilator FEV1/FVC &lt; 0.7 Smokers exsmokers least 20 packyear smoke history Able communicate meaningfully study personnel understand read fluently English Written inform consent ; BODE score 310 . History Omalizumab use Evidence illicit drug use abuse alcohol . Women childbearing potential use contraception method ( ) specify study ( specify ) , well woman breastfeed Known sensitivity study drug ( ) class study drug ( ) Patients severe medical condition ( ) view investigator prohibit participation study ( specify require ) Use investigational agent last 30 day Continuous treatment oral corticosteroid Participating another trial within 3 month prior begin study Noncompliance take medication Planned lung transplantation time admission study expect transplant within 3 yr Alpha1antitrypsin deficiency Cystic fibrosis Bronchiectasis History infection active infection due Mycobacterium tuberculosis Pneumoconiosis Pulmonary restriction due pulmonary disease , apart one concerned study population Congestive heart failure class 2 New York Heart Association ( NYHA ) Reduced life expectancy due disease ( define expect mortality ≥25 % five year enrollment ) Current use ßblockers</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>Exacerbation</keyword>
</DOC>